Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB5 | P28074 | 18/20 | 0.68 |
| ▸ | PSMB2 | P49721 | 15/20 | 0.68 |
| ▸ | PSMB1 | P20618 | 14/20 | 0.68 |
| ▸ | PSMB8 | P28062 | 12/20 | 0.68 |
| ▸ | PSMB9 | P28065 | 12/20 | 0.68 |
| ▸ | PSMB10 | P40306 | 12/20 | 0.68 |
| ▸ | PSMB11 | A5LHX3 | 11/20 | 0.68 |
| ▸ | PSMA7 | O14818 | 11/20 | 0.68 |
| ▸ | PSMA1 | P25786 | 11/20 | 0.68 |
| ▸ | PSMA2 | P25787 | 11/20 | 0.68 |
| ▸ | PSMA3 | P25788 | 11/20 | 0.68 |
| ▸ | PSMA4 | P25789 | 11/20 | 0.68 |
| ▸ | PSMA5 | P28066 | 11/20 | 0.68 |
| ▸ | PSMB4 | P28070 | 11/20 | 0.68 |
| ▸ | PSMB6 | P28072 | 11/20 | 0.68 |
| ▸ | PSMB3 | P49720 | 11/20 | 0.68 |
| ▸ | PSMA6 | P60900 | 11/20 | 0.68 |
| ▸ | PSMA8 | Q8TAA3 | 11/20 | 0.68 |
| ▸ | PSMB7 | Q99436 | 11/20 | 0.68 |
| ▸ | PSMD11 | O00231 | 3/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2632870 | 0.95 | PSMB5 (0.69) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL2735615 | 0.94 | PSMB5 (0.68) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL17298373 | 0.89 | PSMB5 (0.69) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL22733288 | 0.87 | PSMB5 (0.73) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL17298374 | 0.87 | PSMB5 (0.67) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL24025122 | 0.86 | PSMB5 (0.72) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL22062305 | 0.86 | PSMB5 (0.72) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL16104642 | 0.86 | PSMB5 (0.72) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL23710789 | 0.86 | PSMB5 (0.72) | PSMB5PSMB2PSMB1PSMB8PSMB9 | |
| SCHEMBL15866465 | 0.86 | PSMB5 (0.60) | PSMB5PSMB2PSMB1PSMB8PSMB9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | US | disclosed |
| US-8088741-B2 | Compounds for enzyme inhibition | ONYX THERAPEUTICS, INC. (US) | 2012-01-03 | — | — | US | disclosed |
| EP-2030981-A1 | Compounds for proteasome enzyme inhibition | Proteolix, Inc. (US) | 2009-03-04 | — | — | EP | disclosed |
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | PROTEOLIX, INC. (US) | 2008-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080090785-A1 | Peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases, e.g., the chymotrypsin-like activity of the 20S proteasome; antiproliferative and antiinflammatory agents | ANPEP, DNPEP, CPN1 | PSMB5 25/4885PSMB2 13/4885PSMB1 4/4885 |
| US-20120101026-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PSMB5 29/4885PSMB2 14/4885PSMB1 7/4885 |
| US-20120101025-A1 | Compounds For Enzyme Inhibition | ANPEP, DNPEP, CPN1 | PSMB5 29/4885PSMB2 14/4885PSMB1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.